IL17A and infectious colitis: Given the significant role of IL-17A in the homeostasis of the intestinal mucosa and the potential risk of infectious colitis and new-onset IBD under IL-17A-inhibitor therapy, it is crucial for healthcare providers to carefully select patients for this treatment and inform them about the potential side effects.